

Edgar Filing: SERONO S A - Form 6-K

SERONO S A
Form 6-K
April 30, 2004

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2004

Serono S.A.

(Registrant's Name)

15 bis, Chemin des Mines
Case Postale 54
CH-1211 Geneva 20
Switzerland

(Address of Principal Executive Offices)

1-15096

(Commission File No.)

(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)

Form 20-F Form 40-F

(Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b)(1).)

(Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b)(7).)

(Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)

Yes No
--- ---

(If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-)

SERONO

Edgar Filing: SERONO S A - Form 6-K

Media Release

FOR IMMEDIATE RELEASE

POSITIVE RESULTS FOR RAPTIVA(R) (EFALIZUMAB) IN FIRST PSORIASIS STUDY
OUTSIDE OF THE UNITED STATES

Treatment response in line with previous studies

GENEVA, SWITZERLAND - APRIL 30, 2004 - Serono (virt-x: SEO and NYSE: SRA) announced today the results from the CLEAR trial, the first randomized placebo-controlled, study with Raptiva(R) (efalizumab) conducted outside of the United States. The results of CLEAR demonstrate that Raptiva is safe and efficacious. They are also consistent with the previous trials which formed the basis for the approval of Raptiva for chronic moderate-to-severe plaque psoriasis in the US and Switzerland.

In the 793 patient multi-center study, 31.4% of patients treated with Raptiva once a week for a period of 12 weeks showed a 75% or greater improvement in their Psoriasis Area and Severity Index (PASI 75) score versus 4.2% of patients on placebo (p